Thermo Fisher Likely to Benefit From End-Market Recovery, but Structural Risks Remain, RBC Says

MT Newswires Live05-16

Thermo Fisher Scientific (TMO) could benefit from improving end-market conditions and recovering biotech funding, though "structural risks" may limit the company's ability to achieve its long-term organic growth aspiration, RBC Capital Markets said in a report emailed Friday.

"Investor skepticism" surrounding Thermo Fisher's 2026 guidance and broader post-pandemic recovery trends "is well-founded" after several years of uneven "normalization" across the life sciences tools industry, RBC noted. Still, the firm said recovery prospects appear "more plausible" as uncertainty in large pharmaceutical and academic markets begin to ease.

The firm said normalized organic growth closer to 5% may be as likely as management's 7%-plus target and the Wall Street's roughly 6% forecast. It also pointed to "lingering" artificial intelligence uncertainty surrounding the long-term outlook for the company's contract research organization business, which represents about 20% of sales, according to the report.

RBC resumed coverage of Thermo Fisher with a sector perform rating and a $490 price target.

Price: 442.17, Change: -6.04, Percent Change: -1.35

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment